Articles tagged with Vaccination
Research suggests that children allergic to eggs are not at a higher risk of anaphylaxis from the measles, mumps and rubella (MMR) vaccine. A growing body of evidence shows that only minor reactions may occur in some cases.
A new nicotine vaccine has been developed to prevent and treat tobacco addiction by blocking nicotine from reaching the brain. The vaccine, which uses antibodies to bind to nicotine, has shown promising results in laboratory studies, reducing nicotine levels in the brain by up to 64%.
Dr. Rafi Ahmed will deliver a lecture on immune memory to viruses as part of the 1999 Tadeusz J. Wiktor Memorial Lecture series at The Wistar Institute. His research focuses on chronic viral infections and immunology, building on his PhD in Microbiology and Molecular Genetics from Harvard.
Researchers have identified a substance produced by the tuberculosis bacterium that triggers an immune response, suggesting it could enhance vaccine effectiveness. The substance, combined with vaccines, may push the body's immune system in the right direction to fight tuberculosis and other microbial infections.
Researchers found that vaccinated patients had a significantly lower chance of death and relapse compared to non-vaccinated patients. The THERATOPEO vaccine increased specific killing activity against cancer cells, leading to longer remission periods.
Jefferson researchers report progress in using a vaccinia-based vaccine to treat advanced melanoma, with two patients achieving complete remission. The vaccine works by boosting the immune system with granulocyte macrophage colony stimulating factor (GM-CSF), but more research is needed to enhance the treatment.
Weizmann Institute scientists develop a heat-shock protein-based vaccine that triggers high-performance antibodies against bacterial infections, providing nearly complete protection against lethal doses. The new approach may lead to improved vaccines for various diseases and potentially cancer therapy.
The article discusses various public health issues, including tobacco control, food industry manipulation, and violence prevention. It highlights the importance of vaccination coverage estimation using parental recall, medical records, and other methods to prevent diseases such as tuberculosis.
Researchers at the University of Michigan have developed a vaccine made from dendritic cells that triggers the immune system to attack malignant tumors and prevent new tumor development in mice. The study found significant results, including a 70% kill rate of sarcoma cells within four hours.
A human clinical trial of an edible vaccine has shown promising results, indicating that consumption can result in immunity to specific diseases. The vaccine was tested on volunteers who ate genetically altered potatoes and showed a significant immune response, with antibodies found in both blood and stool samples.
Researchers have shown that an edible vaccine can safely trigger significant immune responses in humans. Ten of the 11 volunteers who ingested transgenic potatoes had fourfold rises in serum antibodies, and six developed intestinal antibodies. The study demonstrates a potential solution for reducing vaccine burden in developing countries.
Researchers at Thomas Jefferson University have created an autologous ovarian cancer vaccine that stimulates an immune response in patients, showing promise for treatment. The vaccine is custom-made for each patient and has been safe with no significant side effects, paving the way for further clinical trials.
Researchers found that ewes' antibodies are passed to lambs through colostrum, making vaccination unnecessary until past the age of 6 weeks. This schedule change can save time and energy for farmers, with significant benefits for national agriculture.
Researchers have discovered that killer lymphocytes recognising HPV can be found in tumour tissues, and that they may be able to boost the immune system's response to prevent cancer. A novel vaccine is also being developed to stimulate killer lymphocytes to target HPV-infected cells.
A team of chemists has created a completely synthetic vaccine by synthesizing the epitope of Neisseria meningiditis. The new vaccine uses a system that mimics conventional vaccines and may offer fewer side effects. Researchers are optimistic about the potential for this technology to improve vaccine development in the future.
Researchers create a novel form of botulinum toxin that survives the gastrointestinal system and can be used as an effective oral vaccine. This breakthrough has far-reaching implications for developing vaccines against diseases such as diphtheria, tetanus, and whooping cough.
A new experimental vaccine has been developed to block viral entry in cattle, which may have implications for the development of vaccines against human herpes viruses. The vaccine stimulates the animal's immune system to make antibodies that line the nasal passages and block the virus from entering the animal.
Researchers discovered a strong correlation between mumps virus infection and infantile rapid progression of congestive heart failure (EFE), with 72% of cases positive for the virus. The study's findings support the development of a vaccine against adenovirus, which is currently being produced but not widely available.
Researchers developed a conjugate vaccine that stimulates strong immune responses and neutralizes bacteria, providing protection to newborns. The study found that antibodies isolated from immunized women can cross the placenta and protect infants from infection.
Researchers successfully engineer a protein-based vaccine that primes killer T cells to respond against infection, providing protection against a model pathogen. The approach shows promise for developing new vaccines against viruses, bacteria, and parasites, as well as cancer vaccines and therapies.
Scientists have developed a new vaccine that uses an anti-idiotype antibody to stimulate the immune system and prevent Chlamydia trachomatis infections, which affect 700 million people worldwide. The vaccine was effective in animal experiments and may be available for humans with further development.
Researchers at Texas A&M University and MedImmune have developed a new vaccine candidate that appears to offer protection against Lyme disease. The vaccine is based on a protein from the Lyme-causing bacterium and has been shown to clear the disease-causing organisms from the body even after infection.